Drugs / TDV
last change Jan 2026 re-read 3 minutes ago

TDV

Vaccine

Developed for
dengue disease
Investigated by
Takeda

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06579755 Jan 2026 → Apr 2027 expected dengue disease Takeda Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TDV ClinicalTrials.gov intervention name — accepted as the source's own label NCT06579755 ↗
Modality Vaccine “Dengue Tetravalent Vaccine (TDV)” NCT06579755 ↗
Route Subcutaneous “TDV, 0.5 mL subcutaneous (SC) injections” NCT06579755 ↗